Neomatrix, an Italian biotechnology company specializing in the development of personalized cancer vaccines based on synthetic DNA, announces that Lucio Rovati, founder and CEO of Rottapharm Biotech, a leading figure in the Italian and international pharmaceutical industry, has joined its investors.
The investment, made through Fidim, the holding company to which Rottapharm Biotech belongs, represents an important step forward in Neomatrix’s growth. Beyond providing financial support, Lucio Rovati will also make the experience and expertise of the Rottapharm Biotech team available to the company, particularly in the clinical and regulatory development of innovative therapies. The aim is to accelerate the clinical development of Neo-Lin, Neomatrix’s personalized therapeutic vaccine, initially targeting patients with non-small cell lung cancer.
“We are extremely pleased and excited about this new collaboration with Lucio Rovati, who represents an extraordinarily valuable strategic partner for us,” says Luigi Aurisicchio, CEO and co-founder of Neomatrix. “Together with Takis and Rottapharm Biotech, we have gained invaluable experience through the development of COVID-eVax, one of the first DNA vaccines against COVID-19 to enter clinical trials, successfully completing a Phase I study. This experience is now complemented by the highly specialized expertise of the Neomatrix team in immuno-oncology, neoantigen selection and personalized vaccine development. With Rottapharm Biotech joining our investors, we can build on an already well-established complementarity of expertise, which is particularly important in the transition from research to clinical development. Our goal is to initiate the first clinical trial of Neo-Lin in 2027, bringing an innovative technology, conceived and developed in Italy, to patients.”
The investment comes at a particularly significant time for the cancer immunotherapy field. The recent positive results of the Phase III study conducted by Moderna and Merck/MSD on a personalized mRNA vaccine targeting tumor neoantigens, in combination with pembrolizumab for the adjuvant treatment of surgically resected melanoma, represent a major milestone for the entire field, confirming the clinical potential of this new class of therapies.
“We are living through a historic moment for personalized cancer vaccines,” says Fabio Palombo, CSO and co-founder of Neomatrix. “The Phase III results from Moderna and Merck provide important validation of the therapeutic potential of vaccines targeting tumor neoantigens. They demonstrate that a complex approach, developed through more than a decade of scientific research, can translate into tangible clinical benefits for patients. Neomatrix is part of this evolving landscape with a platform that combines proprietary machine learning-based technologies for therapeutic target identification with fully synthetic DNA vaccines, offering promising advantages in terms of production speed, flexibility and sustainability. Our preclinical results encourage us to continue working towards the clinical validation of this platform with determination.”
Neomatrix’s technology combines advanced bioinformatics and machine learning algorithms with a synthetic DNA production platform, with the aim of developing affordable and sustainable personalized cancer vaccines for healthcare systems. This approach seeks to expand the range of tumor neoantigens that can be used as vaccine targets, including those that may be overlooked by conventional selection methods, and to stimulate immune responses against a broader range of tumor-specific targets.
Our group has decided to invest in Neomatrix because I firmly believe in the quality of its research, the strength of its team and the potential of its technology. Personalized medicine, and therapeutic cancer vaccines in particular, represents one of the most promising frontiers in pharmaceutical innovation. Our contribution will go beyond financial investment: we want to make Neomatrix benefit from the extensive scientific, clinical and industrial expertise we have built up over decades of drug development, supporting the company’s management team through the next stages of growth. We are particularly excited about the opportunity to help bring an original technology into clinical development: a personalized cancer vaccine developed in Italy, with the ambition of offering patients new therapeutic opportunities while showcasing the excellence of biotechnology research in our country.
Lucio Rovati, founder and CEO of Rottapharm Biotech
The investment by Lucio Rovati and Rottapharm Biotech therefore strengthens Neomatrix’s path towards clinical development and reflects growing interest in technologies that combine immunotherapy, genomics and precision medicine, helping to build an Italian innovation ecosystem in oncology.
Neomatrix is an Italian biotechnology company founded in 2020 as a spin-off of Rome-based Takis. In 2023, the company secured investment from two investors: 2Invest (Germany) and i2i (UK). Neomatrix develops personalized cancer vaccines based on patient-specific neoantigens, identified through genomic analysis and proprietary bioinformatics algorithms. Its Neo-Lin platform combines synthetic DNA with innovative delivery technologies, with the aim of making personalized immunotherapies more accessible and sustainable. Its first clinical development program focuses on non-small cell lung cancer.
Lucio Rovati is a physician and clinical pharmacologist, and the founder and CEO of Rottapharm Biotech. He has extensive international experience in research, clinical development and pharmaceutical innovation. Founded in 2014, Rottapharm Biotech is part of the Fidim Group and is committed to researching and developing new therapeutic solutions, drawing on established scientific and industrial expertise in the pharmaceutical sector.






